Focusing on the research and development of a new generation of radiopharmaceuticals, this pharmaceutical company completed over 300 million yuan in financing

According to WHO statistics, the number of new cancer patients in China in 2020 will be 4.
57 million
.
Radiotherapy is one of the main methods for treating malignant tumors
.
It is understood that in China, about 70% of patients with malignant tumors need to receive radiotherapy
.
However, although traditional radiotherapy can achieve the purpose of killing cancer cells, it also has many side effects, which can bring pain to patients
.
Innovative radiopharmaceuticals can kill tumors while reducing side effects
.
With the targeted clinical application of radioisotopes in recent years, the global radiopharmaceutical market has grown rapidly.
Data shows that the global radiopharmaceutical market will reach 7.
1 billion U.
S.
dollars in 2020, and this market is expected to reach 26 billion U.
S.
dollars by 2030
.
Compared with Western countries, although domestic nuclear medicine started late, the Chinese radiopharmaceutical market only accounts for less than 7% of the global market
.
However, with the release of domestic programmatic industrial documents, the application of radiopharmaceuticals to the MAH system, and the liberalization of nuclear medicine equipment configuration certificates, the industry expects that the domestic radiopharmaceutical market will also usher in a booming development
.
In this context, in recent years, many local pharmaceutical companies are actively deploying in the field of radiopharmaceuticals.
At the same time, the vast space for the development of the radiopharmaceutical market has also attracted a large amount of capital
.
For example, Xiantong Pharmaceutical recently announced the completion of a 320 million yuan D+ round of financing.
This round of financing was jointly invested by China Life Health Fund and Dazheng Capital.
Existing shareholders Panya Investment, Deyi Capital, etc.
continue to participate in the investment, and Kaicheng Capital provides A lot of help and support
.
Prior to this, Xiantong Pharmaceutical had completed the D round of financing led by CICC Qide, co-invested by a series of institutions, and the original institutional shareholder Hetang Venture Capital in February 2021
.
In addition, since 2016, the company has successively completed multiple rounds of financing
.
Among them, in July 2016, Xiantong Pharmaceutical completed a 100 million yuan A round of financing, Wuming Investment’s funds invested a total of 70 million yuan, and the management team followed up with the same valuation of 30 million yuan; in November 2017, 150 million yuan of financing was completed; On September 8, 2020, 280 million yuan of C round of financing was completed.
Investment institutions include Tongfu Fund, Sinopharm Capital, Wuming Investment, Guokejiahe and Hetang Venture Capital
.
It can be seen that the capital market highly recognizes the strong nuclear drug innovation and research and development capabilities of Xiantong Pharmaceutical
.
It is reported that the funds raised this time will continue to be used for clinical research and development of new radioactive drug projects
.
According to data, Xiantong Pharmaceutical is an innovative pharmaceutical company that focuses on the research and development, production and clinical application of a new generation of radiopharmaceuticals, and deeply cultivates a rich product line of integrated radiological targeted diagnosis and treatment
.
The company is headquartered in the capital, Beijing, and has modern radiopharmaceutical production bases in Jiangsu, Guangdong and Sichuan, and branches in the United States
.
At present, the company has deployed a variety of targeted therapies and precise diagnostic radiopharmaceuticals in the fields of tumors, neurodegenerative diseases and cardiovascular diseases.
Relying on the strong R&D capabilities of the independent R&D team, the company has deployed multiple radiological diagnostic and therapeutic products in the pipeline.
Part of it has entered the stage of registered clinical research
.
According to the next step of Xiantong Medicine, the development of radiopharmaceuticals has entered the fast lane with the gradual popularization of domestic nuclear medicine equipment and the continuous emergence of new nuclide drugs
.
Compared with developed countries in Europe and the United States, although the domestic nuclear medicine field is still in its infancy, Xiantong Pharmaceutical firmly believes that it will catch up quickly and will do its best to develop radiopharmaceutical products to contribute to the rise of China's radiopharmaceutical industry
.